🔎 Trials Near Me

Hjem › Akut myeloid leukæmi › Rhode Island

Akut myeloid leukæmi kliniske forsøg i Rhode Island

11 studier for Akut myeloid leukæmi søger deltagere på steder i Rhode Island.

Byer i Rhode Island

Officiel studietekst (engelsk)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Kent Hospital, Warwick
RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
Alder 40 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Rhode Island Hospital, Providence
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 28. sep. 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Rhode Island Hospital, Providence
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT05564390

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Providence
RekruttererFase 3
Alder 12 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT07211958

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Rhode Island Hospital, Providence
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Rhode Island Hospital, Providence
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Rhode Island Hospital, Providence
RekruttererFase 2
Alder 18 til 59 · Alle køn · Opdateret 22. sep. 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Rhode Island Hospital, Providence
RekruttererFase 3
6 Months – 21 Years · Alle køn · Opdateret 17. sep. 2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Rhode Island Hospital, Providence
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  • University of Rhode Island, Providence
RekruttererFase 2/3
Alder 18 til 80 · Alle køn · Opdateret 5. aug. 2026 · NCT06788756

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  • Lifespan Health System Rhode Island Hospital, Providence
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 10. jul. 2026 · NCT05442216

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.